Risklick’s Protocol AI is end-to-end AI software for developing clinical trial protocols and study plans. It is built around a three-step workflow — “Explore, Design, Develop” — to help experts systematically analyze study design factors, generate multiple design scenarios, and use customized generative AI to quickly produce protocols and research plans. Its positioning is not that of a general-purpose writing tool, but a specialized platform for pharmaceutical companies, CROs, and clinical R&D teams.
The product emphasizes evidence-based protocol development. Under the hood, it is supported by a comprehensive database of more than 800,000 clinical trials, linked to sources such as publications, regulatory approvals, and safety data. It supports ICH M11 and USDM-standard Digital Protocols, can adapt to different protocol templates, and exports to Word, Excel, or JSON. The platform can also integrate with electronic clinical trial systems such as EDC and eTMF for downstream implementation and change management. The copy states that it can reduce protocol and study plan development time by 50%, revisions by 20%, and implementation time by 40%, but does not provide an independently verifiable methodology.
The official website does not disclose specific pricing, nor does it mention a free tier or self-service trial. Access mainly starts through a Request a Demo sales process. The terms indicate that it uses subscription plans, with fees paid in advance and limits on user count, duration, and features depending on the package. For support, it provides 24/7 ticket and email support, with a maximum response time of 24 hours. On data compliance, the platform states that it complies with GDPR and has ISO 27001:2022 compliance. Customer materials remain owned by the customer, while Risklick is granted permission to use them to provide and improve the service.
Its strengths are its domain focus, tight coupling between its database and clinical trial standards, and consideration for practical EDC/eTMF implementation workflows. Role-based permissions, collaboration features, and interconnected documents also make it suitable for team-based R&D. The limitations are that the underlying model, generation accuracy, validation mechanisms, pricing, and Chinese-language support are not disclosed. Generated content should still be reviewed by medical, statistical, regulatory, and operational experts. It is suitable for pharmaceutical companies, biotech firms, CROs, and research institutions that already have established clinical R&D workflows. It is not intended for general document writing or lightweight AI office productivity needs.
There is no clear information on access from mainland China, payment methods, or local deployment, so china access is currently assessed as unknown. Companies planning to use it in China should focus on confirming network connectivity, GDPR/cross-border data considerations, contract payment methods, and support for the Chinese regulatory context. Alternatives worth considering include clinical R&D platforms such as Veeva, Medidata, and Oracle Clinical One, or traditional CRO medical writing services. General-purpose large language models can assist with drafting, but they lack this type of dedicated evidence base and clinical system integration.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on risklick.com official site.
risklick.com is an Switzerland AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach risklick.com directly.